Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin, quantity: 3.33 mg/ml - injection, solution - excipient ingredients: mannitol; histidine; water for injections; phenol; poloxamer - children:treatment of growth failure in children due to pituitary growth hormone deficiency. treatment of growth failure in girls due to gonadal dysgenesis (turner's syndrome). treatment of growth failure in children due to chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2. treatment of severe growth failure due to intrauterine growth retardation (i.e., children born small for gestational age (birth weight and/or length < -2 sd) without spontaneous catch up growth by 2 years of age). adults: treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. in order to establish childhood onset [co] growth hormone insufficiency, reconfirmation by one provocative test is recommended. in order to establish isolated growth hormone deficiency two provocative tests are recommended. in adults, the insulin tolerance test is the provocative test of choice. when the insulin tolerance test is contraindicated, alternative provocative tests must be used. the combined arginine or the glucagon test may also be considered; however these tests have less established diagnostic value than the insulin tolerance test.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - atropine sulfate - solution for injection in a pre-filled syringe - atropine sulfate 0.1 mg/ml - drugs for functional gastrointestinal disorders

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - atropine sulfate - solution for injection in a pre-filled syringe - atropine sulfate 0.1 mg/ml - drugs for functional gastrointestinal disorders

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - atropine sulfate monohydrate, quantity: 600 microgram/ml; sodium hydroxide - injection, solution - excipient ingredients: water for injections; sodium chloride; sulfuric acid - indications as at 30 september 2003:surgery : atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. the use of atropine as an antisialogogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. after surgery atropine may also be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) when used to terminate curarisation to counteract the adverse muscarinic effects of these drugs. cardiopulmonary resuscitation : atropine may be used during cardiopulmonary resuscitation to treat sinus bradycardia and associated hypotension, and increased ventricular irritability. anticholinesterase poisoning : atropine juno is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, amanita muscaria mushrooms or other compounds with anticholinesterase activity. a cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently.

Kenya - English - Pharmacy and Poisons Board

vital healthcare pvt ltd off mombasa road masai raod nairobi kenya - atropine sulfate bp - injection - atropine sulfate bp 1mg/ml - atropine

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aguettant ltd - atropine sulfate - solution for injection - 200microgram/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

phebra nz limited - benzatropine mesilate 1 mg/ml - solution for injection - 2 mg/2ml - active: benzatropine mesilate 1 mg/ml excipient: sodium chloride water for injection - benzatropine injection is recommended for all forms of parkinsonism including arteriosclerotic, post-encephalitic, idiopathic, as well as medicine-induced extrapyramidal disorders (except tardive dyskinesia). it can be effective at any stage of the disease, even when a patient has become bedridden. benzatropine injection often is helpful in patients who have become unresponsive to other agents. benzatropine injection is a powerful anticholinergic agent which is mainly effective in relieving tremor and rigidity. therapy is directed toward control of disturbing symptoms to permit the patient maximum integration of function with minimum discomfort. in non-medicine-induced parkinsonism, partial control of symptoms is usually achieved.

Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - atropine sulfate monohydrate, quantity: 1.2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - indications as at 23 october 2001: preanaesthetic medication to reduce salivary secretions and bronchial secretions. to prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia. management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability. concurrent administration with anticholinesterase agents (eg. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation. for poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - atropine sulfate monohydrate 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: atropine sulfate monohydrate 0.1 mg/ml excipient: citric acid monohydrate sodium chloride sodium citrate dihydrate water for injection - in the management of patients with severe bradycardia and bradyarrhythmias to increase the heart rate. patients with type i atrioventricular conduction deficits to lessen the degree of atrioventricular heart block.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - midazolam 1 mg/ml;   - solution for injection - 1 mg/ml - active: midazolam 1 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - conscious sedation before diagnostic or surgical interventions carried out under local anaesthesia (intravenous administration), or in children intranasal or oral administration. long-term sedation in intensive care units (intravenous administration as bolus injection or continuous infusion).